Initiator Pharma A/S
STO:INIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Entheon Biomedical Corp
CNSX:ENBI
|
CA |
|
T
|
Twin Hospitality Group Inc
NASDAQ:TWNP
|
US |
Initiator Pharma A/S
Total Current Liabilities
Initiator Pharma A/S
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Initiator Pharma A/S
STO:INIT
|
Total Current Liabilities
kr1.3m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Total Current Liabilities
kr1.4B
|
CAGR 3-Years
76%
|
CAGR 5-Years
47%
|
CAGR 10-Years
37%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Current Liabilities
kr665m
|
CAGR 3-Years
50%
|
CAGR 5-Years
13%
|
CAGR 10-Years
25%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Total Current Liabilities
$1.2m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Current Liabilities
€1.1B
|
CAGR 3-Years
84%
|
CAGR 5-Years
83%
|
CAGR 10-Years
57%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Current Liabilities
kr1.6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
Initiator Pharma A/S
Glance View
Initiator Pharma A/S is a clinical-stage biotechnology company, which engages in the development of novel therapeutics within the field of mono-amine reuptake transporters targeting central nervous system (CNS)-disorders. The firm focuses on developing drugs for treatment of erectile dysfunction.
See Also
What is Initiator Pharma A/S's Total Current Liabilities?
Total Current Liabilities
1.1m
DKK
Based on the financial report for Dec 31, 2024, Initiator Pharma A/S's Total Current Liabilities amounts to 1.1m DKK.
What is Initiator Pharma A/S's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-7%
Over the last year, the Total Current Liabilities growth was -67%. The average annual Total Current Liabilities growth rates for Initiator Pharma A/S have been -42% over the past three years , -7% over the past five years .
